Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine.

Abstract

Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but a substantial proportion of patients either do not respond to treatment or lose response over time. Drug immunogenicity, manifested as the formation of anti-drug antibodies (ADAb), constitute a significant clinical problem. Anti-drug antibodies influence the pharmacokinetics of the drug, are associated with reduced clinical efficacy, and an increased risk of adverse events such as infusion reactions. The prevalence of ADAb differs among drugs and diseases, and the detection of ADAb also depends on the assay format. Most data exist for the tumor necrosis factor-alpha inhibitors infliximab and adalimumab, with a frequency of ADAb that ranges from 10 to 60% across studies. Measurement of ADAb and serum drug concentrations, therapeutic drug monitoring, has been suggested as a strategy to optimize therapy with biologic drugs. Although the recent randomized clinical Norwegian Drug Monitoring (NOR-DRUM) trials show promise towards a personalized medicine prescribing approach by therapeutic drug monitoring, several challenges remain. A plethora of assay formats, with widely differing properties, is currently used for measuring ADAb. Comparing results between different assays and laboratories is difficult, which complicates the development of cut-offs necessary for guidelines and the implementation of ADAb measurements in clinical practice. With the possible exception of infliximab, limited data on clinical relevance and cost effectiveness exist to support therapeutic drug monitoring as a routine clinical strategy to monitor biologic drugs in inflammatory joint diseases. The aim of this review is to provide an overview of the characteristics and prevalence of ADAb, predisposing factors to ADAb formation, commonly used assessment methods, clinical consequences of ADAb, and the potential implications of ADAb assessments for everyday treatment of inflammatory joint diseases.

• Authors: Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, Meghna Jani, Nils Bolstad, Silje Watterdal Syversen
• Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (BioDrugs) Vol. 36 Issue 6 Pg. 731-748 (Nov 2022) ISSN: 1179-190X [Electronic] New Zealand
• PMID: 36315391 (Publication Type: Journal Article, Review)
• Copyright: © 2022. The Author(s).

Chemical References

• Infliximab
• Antirheumatic Agents
• Biological Products
• Adalimumab
• Antibodies
• Tumor Necrosis Factor-alpha

Topics

• Humans
• Infliximab (adverse effects, pharmacokinetics)
• Antirheumatic Agents (adverse effects)
• Biological Products
• Precision Medicine
• Adalimumab (adverse effects)
• Antibodies
• Joint Diseases (drug therapy)
• Tumor Necrosis Factor-alpha